CFTR modulators portfolio of Vertex Pharmaceuticals supports a value of $297 per share. Relative to this, the share price of $228.22 (as of Jan 27, 2022) represents an undervaluation of at least 30%. The four CFTR modulators portfolio of VRTX are expected to generate a revenue of $7.9B in 2022 and grow to $9.4B in 2026.